30th Mar 2015 15:47
4D pharma plc
(the 'Company' or '4D')
Acquisition of minority interests
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, is pleased to confirm that it has acquired the remaining minority interests in GT Biologics Limited, amounting, in aggregate, to approximately 16.5% of its issued share capital, which is now wholly owned and has been renamed 4D pharma Research Limited.
For further information please contact:
4D | + 44 (0) 161 837 6205 |
Duncan Peyton, Chief Executive Officer
| |
Zeus Capital Limited - Nomad and Broker | |
Dan Bate/Ross Andrews | +44 (0) 161 831 1512 |
Dominic Wilson | +44 (0) 20 7533 7727 |
Related Shares:
DDDD.L